Online citations, reference lists, and bibliographies.
← Back to Search

Safety And Efficacy Of Lamivudine-zidovudine Combination Therapy In Antiretroviral-naive Patients : A Randomized Controlled Comparison With Zidovudine Monotherapy

C. Katlama, D. Ingrand, C. Loveday, N. Clumeck, J. Mallolas, S. Staszewski, M. Johnson, A. Hill, G. Pearce, H. McDade
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Objective.-To compare safety and efficacy of lamivudine-zidovudine combination therapy with zidovudine monotherapy in treating human immunodeficiency virus type 1 (HIV-1)-infected, antiretroviral therapy-naive patients. Design.-Double-blind, randomized, multicenter, comparative trial of 129 patients throughout 24 weeks followed by 24 weeks of open-label lamivudine in combination with zidovudine. Setting.-Outpatients from 14 hospitals in Belgium, France, Germany, Spain, and the United Kingdom were enrolled within 6 months. Patients.-HIV-1-positive, antiretroviral-naive (less than or equal to 4 weeks prior zidovudine use) patients aged at least 18 years with CD4(+) cell counts between 0.10 x 10(9)/L and 0.40 x 10(9)/L (100-400/mu L). Intervention.-Patients received either 300 mg of lamivudine every 12 hours in combination with 200 mg of zidovudine every 8 hours for 24 weeks or zidovudine monotherapy for 24 weeks. All patients were then allowed to receive zidovudine in combination with open-label lamivudine (300 mg every 12 hours). Main Outcome Measures.-Efficacy was assessed by changes in CD4(+) cell counts, beta(2)-microglobulin, neopterin, HIV-1 immune-complex dissociated (ICD) p24 antigenemia, and HIV-1 viral load. Safety was assessed by incidence of adverse clinical events and defined laboratory-measured toxic effects. Results.-Combination therapy showed superior treatment effects compared with monotherapy during the first 24 weeks as documented by changes in CD4(+) cell counts (increase of 0.08 x 10(9)/L vs 0.02 x 10(9)/L, P<.001), ICD p24 (-88% vs -49%; P=.04), cellular viremia (-1.27 vs -0.20 log(10) median tissue-culture infected dose [TCID50] per 10(6) peripheral blood mononuclear cells; P=.001), and viral load measured by HIV-1 RNA polymerase chain reaction using a Roche method (-1.33 vs -0.57 log(10) copies/mL; P=.001) or an immune-capture method (-0.6 vs -0.14 log,, copies/mL; P=.008). Observed changes were sustained to 48 weeks for patients continuing to receive combination therapy. Patients switching to receive combination therapy at week 24 showed improvements in CD4(+) cell count and viral load to week 48. Mutation results suggested that mutations associated with zidovudine resistance may have developed more slowly over the first 24 weeks in patients receiving combination therapy. In contrast, mutations associated with lamivudine resistance appeared to develop rapidly, despite sustained antiviral treatment effect. However, the number of patients evaluated for genotypic changes was small, and confirmation of these results is needed in larger studies. No statistically significant differences in incidence or severity of clinically manifested or laboratory-measured toxic effects were noted between treatment groups. Conclusions.-The combination of lamivudine and zidovudine results in a potent and sustained antiviral effect in antiretroviral-naive patients that is superior to that observed with zidovudine monotherapy.
This paper references
10.1056/NEJM198707233170401
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
10.7326/0003-4819-112-10-727
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial
M. Fischl (1990)
10.1056/NEJM199004053221401
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
P. Volberding (1990)
10.1128/JVI.66.12.7128-7135.1992
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine
Z. Gu (1992)
10.1002/JMV.1890370402
A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type‐1 infected patients treated with zidovudine
S. Kaye (1992)
10.1016/0006-2952(92)90093-X
Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells.
J. Sommadossi (1992)
10.1056/NEJM199208273270901
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
J. Kahn (1992)
10.1128/AAC.36.8.1688
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma
G. Hart (1992)
10.1016/0166-0934(93)90124-A
HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials.
M. Semple (1993)
10.1001/JAMA.1993.03510210069030
Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference
M. Sande (1993)
10.1128/AAC.37.6.1390
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
Q. Gao (1993)
10.1016/S0140-6736(94)90006-X
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
Ann Marie Swart (1994)
10.1177/009286159402800308
Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary Measures
J. Dawson (1994)
10.1128/jcm.32.2.292-300.1994
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection
J. Mulder (1994)
10.1038/373123A0
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
D. Ho (1995)
10.1038/373117A0
Viral dynamics in human immunodeficiency virus type 1 infection
X. Wei (1995)
10.1038/NM0795-628
Targeting HIV reverse transcriptase in novel ways
M. Wainberg (1995)
10.1126/SCIENCE.7542804
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
B. Larder (1995)
10.1093/INFDIS/171.6.1411
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
R. Schuurman (1995)
10.1056/NEJM199512213332502
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
J. Eron (1995)
10.1093/INFDIS/171.6.1438
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
J. Pluda (1995)
10.1093/INFDIS/171.5.1166
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
R. van Leeuwen (1995)
10.1128/AAC.39.7.1624
Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
P. Boyer (1995)
10.1172/JCI117698
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.
L. Cui (1995)
10.1126/science.271.5253.1282
Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase
M. Wainberg (1996)
10.1021/BI9516642
Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis.
V. Pandey (1996)
10.1056/NEJM199602153340703
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
W. O'brien (1996)



This paper is referenced by
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
(2020)
10.1111/hiv.12829
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation
O. Stirrup (2020)
10.1080/17425255.2020.1772755
Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection
Piyanuch Wonganan (2020)
HIV Treatment Strategies – The role of integrase strand transfer inhibitors
I. Wijting (2019)
10.1016/J.PROCBIO.2019.03.025
Preparation of the enantiomerically enriched precursor of lamivudine (3TC™) via asymmetric catalysis mediated by Klebsiella oxytoca
Yanming Chen (2019)
10.2147/HIV.S216067
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
Francis J Zamora (2019)
HIV_A_216067 255..263
Francis J Zamora (2019)
10.1097/QAI.0000000000001660
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
R. Quercia (2018)
Artesunate effect on RH virulent and ME 49 non-virulent strains of Toxoplasma gondii : in vitro and in vivo experimental studies
D. Mahmoud (2017)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV
(2017)
10.22028/D291-26681
Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies
A. Pironti (2016)
10.1109/TAES.2016.7472952
From the Managing Editor
Rita Janssen (2016)
Effect of Zidovudine on Hematological and Virologic Parameters among Female Sex Workers Receiving Antiretroviral Therapy (ART) in North-Western Nigeria
N. M. Sani (2015)
10.1111/jep.12122
The timing of introduction of pharmaceutical innovations in seven European countries
R. Westerling (2014)
10.3851/IMP2896
The Discovery and Development of Antiretroviral Agents
J. Lange (2014)
Since the discovery of HIV as the causative agent of AIDS in 1983/1984, remarkable progress
Joep MA Lange (2014)
10.4314/AJCEM.V14I3.1
Prevalence and immune status of HIV/HBV co-infected pregnant women
P. Lar (2013)
Pharmacotherapy of human immunodeficiency virus infection
J. Adams (2013)
10.1371/journal.pone.0061436
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response
J. Vercauteren (2013)
AVALIAÇÃO DO MÉTODO DE DOSEAMENTO DE INDINAVIR POR MEIO DE HPLC
M. Ferrarini (2013)
10.7243/2050-120X-1-4
Reversed Phase LC-UV Method Development and Validation for Simultaneous determination of three antiretrovirals: Lamivudine, Zidovudine, Nevirapine and Possible Degradants in a Fixed Dose Pharmaceutical Product
Anjali Joshi (2012)
10.2165/00019053-199712010-00006
Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection
J. Chancellor (2012)
The investigation of genotypic antiretroviral drug resistance in the context of the South African national antiretroviral roll-out programme
V. Zyl (2012)
10.1111/j.1365-2710.2010.01235.x
Evaluation of steady‐state pharmacokinetic interactions between ritonavir‐boosted BILR 355, a non‐nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects
F. Huang (2012)
10.1517/14656566.2012.642865
Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection
Maxwell O Akanbi (2012)
10.2165/00063030-199708040-00001
Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment
M. Koot (2012)
10.1097/QAI.0b013e31820bd2b6
Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana
S. Dryden-Peterson (2011)
The effects of highly active antiretroviral therapy on survival and CD4 cell percentage in HIV-infected children in Kinshasa, Democratic Republic of Congo
A. Edmonds (2011)
10.1586/erv.11.118
DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS
F. Lori (2011)
Development and Bioavailability/Bioequivalence of a Fixed-Dose Combination Antiretroviral Reconstitutable Suspension Intended for Pediatrics
Fredrick Esseku (2011)
10.1016/j.antiviral.2009.09.015
Clinical management of HIV-1 resistance.
R. Paredes (2010)
10.1097/QAD.0b013e32833ef6c4
CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era
S. Lodi (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar